Accidental
release
|
Any unintended release of regulated
plant material into the environment, food and/or feed chains. For the
purposes of these Guidelines, any breach of the authorized terms and
conditions for reproductive isolation of the confined trial site shall be
considered an accidental release. Accidental release also includes the
spillage, theft, or encroachment by unauthorized persons of regulated GE
plant material during transportation, storage within a contained facility, or
during any other activity associated with the conduct of a confined field
trial. Any accidental release shall be subject to risk assessment, and any
necessary corrective actions shall be at the cost of the applicant or
permitted party.
|
Acute Oral
Toxicity
|
Refers to those adverse effects
occurring following oral administration of a single dose of a substance, or
multiple doses given within 24 hours.
|
Allergen
|
An allergen is a usually harmless
substance capable of triggering a response that starts in the immune system
and results in an allergic reaction.
|
Allergy
|
An allergy is a chronic condition
involving an abnormal reaction to an ordinarily harmless substance called an
allergen.
|
Anthesis
|
The time of flowering or pollination.
Anthesis is complete when flowering or pollination is complete.
|
Anti- nutrient
|
Substance that interferes with the
utilization of one or more nutrients by the body (e.g., oxalate and phytate,
which prevent calcium absorption).
|
Applicant
|
The Applicant must be a permanent
resident of India or must designate an Authorized Signatory (AS) who is a
permanent resident of India. Where an AS is used, there must be a formal, legal
agreement indicating the AS is acting on behalf of the Applicant and both
under the jurisdiction of any Court of Law of India.
A copy of this agreement must be
submitted to the Regulatory Authorities along with the confined field trial
application. The Applicant need not be the breeder/developer or owner of the
regulated plant, in which case a signed statement is required from the
breeder/developer or owner authorizing representation by the Applicant or the
designated AS. All correspondence with respect to the application for a
confined field trial, including the notification of authorization, will be
addressed to the Applicant, or when appropriate, the AS.
|
Biocide
|
A general term for any agent that
kills organisms
|
Biotechnology
|
The application of scientific and
engineering principles to the processing of materials by biological agents to
produce goods and services
|
Breach
|
Any contravention or violation of any
term and/or condition of authorization of a confined field trial will be
considered a breach under these guidelines.
|
Cartagena
Protocol
|
The Cartagena Protocol on Biosafety to
the Convention on Biological Diversity is an international agreement that
aims to ensure the safe handling, transport and use of living modified
organisms (LMOs) resulting from modern biotechnology, which may have adverse
effects on biological diversity, also taking into account risks to human
health. It was adopted on 29 January 2000 and entered into force on 11
September 2003. [1]
|
Codex
Alimentarius
Commission
|
An international
regulatory body (part of the FAO) responsible for the definition of a set of
international food standards. The Commission periodically determines and
publishes a list of food ingredients and maximum allowable levels (the Codex
Alimentarius) deemed to be safe for human consumption.
|
Comparability
exercise
|
Comparison of a Similar Biologic with
a Reference Biologic with the goal to establish Similarity in safety,
efficacy and quality.
|
Confined Field
Trial
|
A confined field trial is a field
experiment of a regulated GE plant under terms and conditions that are
intended to mitigate the establishment and spread of the plant. A single
confined field trial may be comprised of one or more varieties/hybrids of a
single event of a single plant species that are subject to the same terms and
conditions of confinement which include, but are not limited to, reproductive
isolation, site monitoring, and post-harvest land use restrictions. The field
trials are categorized into two types: Biosafety Research Level I and
Biosafety Research Level II trials.
|
Construct
|
An engineered DNA fragment containing,
but not limited to, the DNA sequences to be integrated into the genome of the
target plant.
|
Containment
|
The term “containment” is used to
describe safe methods for managing infectious agents and/or regulated
GMOs/LMOs/rDNA material in the laboratory environment where they are being
handled or maintained.
|
Conventional
counterpart
|
It means the related non-genetically
engineered plant variety, its components and/or products for which there is
experience of established safety based on common use as food.
|
Delayed
Death
|
Means that an animal does not die or
appear moribund within 48 hours but dies later during the 14-day observation
period.
|
Donor
organism
|
Means the organism from which genetic
material is obtained for transfer to the recipient organism.
|
Dose
|
Is the amount of test substance
administered and is expressed as weight of test substance per unit weight of
test animal (e.g., mg/kg).
|
Drug
|
Drug includes (as defined in Drugs and
Cosmetics Act, 1940).
i. all medicines for internal or
external use of human beings or animals and all substances intended to be
used for or in the diagnosis, treatment, mitigation or prevention of any
disease or disorder in human beings or animals, including preparations
applied on human body for the purpose of repelling insects like mosquitoes;
ii. such substances (other than food)
intended to affect the structure or any function of human body or intended to
be used for the destruction of (vermin) or insects which cause disease in
human beings or animals, as may be specified from time to time by the Central
Government by notification in the Official Gazette;
iii. All substances intended for use
as components of a drug including empty gelatine capsules; and
iv. Such devices intended for internal
or external use in the diagnosis, treatment, mitigation or prevention of
disease or disorder in human beings or animals, as may be specified from time
to time by the Central Government by notification in the Official Gazette,
after consultation with the Board.
|
Drug
product
|
The dosage form in the final immediate
packaging intended for marketing. A pharmaceutical product type that contains
a drug substance, generally in association with excipients.
|
Drug
substance
|
Any substance or mixture of substances
intended to be used in the manufacture of a drug(medicinal) product and that,
when used in the production of a drug, becomes an active ingredient of the
drug product. Such substances are intended to furnish pharmacological
activity or other direct effect in the diagnosis, cure, mitigation,
treatment, or prevention of disease or to affect the structure and function
of the body.
|
Early
termination
|
Any termination of a confined field
trial before the anticipated completion date
|
Evident
Toxicity
|
Is a general term describing clear
signs of toxicity following the administration of test substance, such that
at the next highest fixed dose either severe pain and enduring signs of
severe distress, moribund status (criteria are presented in the OECD Guidance
Document on the Recognition, Assessment and Use of Clinical Signs as Humane
Endpoints for Experimental Animals Used in Safety Evaluation), or probable
mortality in most animals can be expected.
Clinical signs that may be indicative of
toxicity include, but are not limited to: rapid weight loss; diarrhoea (if
debilitating); progressive dermatitis; rough hair coat; hunched posture;
lethargy or persistent recumbency; labored breathing; nasal discharge;
jaundice or anaemia; neurological signs; bleeding from any orifice;
self-induced trauma; any condition interfering with eating or drinking (e.g.,
difficulty moving); or excessive or prolonged hyperthermia or hypothermia.
|
Facility
|
The whole of the space that is to be
certified by the Regulator to a specific level of containment.
|
Facility
In-charge
|
The person designated by the permitted
party as responsible for the storage (before or at planting, during planting
and after harvest) of regulated, genetically engineered plant material.
|
Genetic
Engineering (GE)
|
The technique by which heritable
material, which does not usually occur or will not occur naturally in the
organism or cell concerned, generated outside the organism or the cell is
inserted into said cell or organism. It shall also mean the formation of new combinations
of genetic material by incorporation of a cell into a host cell, where they
occur naturally (self-cloning) as well as modification of an organism or in a
cell by deletion and removal of parts of the heritable material
|
GE
Plant
|
A plant in which the genetic material
has been changed through in vitro nucleic acid techniques, including recombinant-deoxyribonucleic
acid (r-DNA) and direct injection of nucleic acid into cells or organelles.
|
Immunogenicity
|
The ability of a substance to trigger
an immune response or reaction (e.g., development of specific antibodies, T
cell response, allergic or anaphylactic reaction).
|
Import permit
|
An official document authorizing
importation of a consignment in accordance with specified phytosanitary
requirements.
|
Impurity
|
Any component present in the drug
substance or drug product that is not the desired product, a product-related
substance, or excipient including buffer components. It may be either
processor product-related.
|
Incident
|
This means unintended release, breach
of containment, spill or occupational exposure to GMOs/LMOs/rDNA materials.
|
Isolation
distance
|
A mandated distance used to spatially
separate a confined field trial from the nearest plant of the same or any
sexually compatible species. Minimum spatial isolation distances vary depending
on the reproductive biology of the plant species, and minimum distances for a
number of plant species have been established by the RCGM.
|
LD50
|
Median lethal oral dose is a
statistically derived single dose of a substance that can beexpected to cause
death in 50 per cent of animals when administered by the oral route. The LD50
value is expressed in terms of weight of test substance per unit weight of
test animal (mg/kg).
|
Limit
Dose
|
Refers to a dose at an upper
limitation on testing (e.g., limit dose of 2000 mg/kg body weight or when
this cannot be achieved in the recommended volume for administration, the
dose used should be the maximum possible based on the solubility of the
protein).
|
Manufacture
|
in relation to any drug includes any
process or part of a process for producing, altering, ornamenting, finishing,
packing, labelling, breaking up or otherwise treating or adopting any drug with
a view to its sale or distribution but does not include the compounding or
dispensing in the ordinary course of retail business; and “to manufacture”
shall be construed accordingly.
|
Moribund
|
Being in a state of dying or inability
to survive, even if treated.
|
Pharmacovigilance
|
The science and activities relating to
the detection, assessment, understanding and prevention of adverse effects or
any other drug related problems.
|
Physical
landmarks
|
Landmarks used to identify or
designate boundaries of a confined field trial site (e.g., telephone poles,
fences, alleys or roads).
|
Plant
material
|
Propagable material (e.g., seed,
transplants, tubers, rhizomes, shoots, budwood, whole plant), and non-propagable
material (e.g., leaves, devitalized material).
|
Post-harvest
period
|
A period of time that follows the
harvest or termination of a confined field trial when restrictions are
imposed on the use of the trial site.
|
Prohibited
plant
|
Plants of any species that are
sexually compatible with the regulated plant under fieldconditions, including
volunteers that may arise in the isolation area during the conduct of
confined field trials
|
Propagable
|
Any plant or plant part that can be
used in the field to regenerate a whole plant under field conditions
|
Protocol
|
The step-by-step experiments proposed
to describe or solve a scientific problem, or the defined steps of a specific
procedure. [17]
|
Reference
Biologic
|
A Reference Biologic is used as the
comparator for comparability studies with the Similar Biologic in order to
show Similarity in terms of safety, efficacy and quality. The Reference
Biologic should be licensed / approved in India or ICH countries and should
be the innovator s product. The Reference Biologic should be licensed based
on a full safety, efficacy and quality data. Therefore another Similar
Biologic cannot be considered as a choice for Reference Biologic
|
Regulatory
Authority
|
As regards confined field trials, RCGM
is the regulatory authority responsible for authorizing Biosafety Research
Level I trials and GEAC is the regulatory authority responsible for
authorizing Biosafety Research Level II trials.
|
Reproductive
isolation
|
Refers to the means used to prevent
movement of plant material, particularly pollen,from a confined field trial
site.
|
Sexually
compatible
|
Ability of a plant to cross-pollinate
with other cultivated plants of the same species, orwith wild plants of a
related species, and form viable hybrids without human intervention.
|
Similar
|
Absence of a relevant difference in
the parameter of interest.
|
Similar
Biologic
|
A Similar Biologic product is that
which is similar in terms of quality, safety and efficacy to an approved
Reference Biological product based on comparability.
|
Stress
|
Non-optimal
conditions for growth. Stresses may be imposed by biotic (pathogens, pests)
or abiotic (environment, such as heat, drought, etc.) factors.
|
Trial site
|
The area where one or more confined
field trials of the same plant species may be grown. For example, three
confined field trials of cotton surrounded by a shared 50 m isolation area
would constitute a single trial site.
|
Trial site
location
|
The geographic location of a confined
trial site, e.g. village, address and plot number.
|
Trial-in-Charge
|
The technical person
designated by the Permitted Party as responsible for management of the field
trial, ensuring compliance with the terms and conditions of a confined field
trial authorization and providing information required by Regulatory
Authorities. The Trial-in-Charge must, at a minimum, be an agriculture
graduate.
|
Volunteers
|
Self-sown plants of the same species
as the regulated plant that may germinate and grow on the trial site and/or
within the isolation distance.
|